Capricor Therapeutics

Allogeneic cardiosphere-derived cell therapies

CAPR · Nasdaq · United States

Share price · CAPR

$8.03+0.95 (+13.42%) 3M

close as of 2026-11-18 · 24h delayed · vol 8.4M (2.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CAPR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+26.5%
  2. 14 Aug 2026+58.0%
  3. 30 Jul 2026-36.2%
  4. 27 Jul 2026-64.5%
  5. 29 Jun 2026-10.0%
  6. 26 Jun 2026-13.0%
  7. 8 May 2026-10.5%
  8. 13 Apr 2026+10.7%

    Nothing announced by CAPR that day or the session before.

  9. 10 Mar 2026+9.0%
  10. 6 Mar 2026+8.1%

    Nothing announced by CAPR that day or the session before.

Share of unusual movement by asset

For each asset, the share of CAPR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
deramiocel
events and moves
2786%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—11%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Cardiac cell therapyCell therapy
Heart FailureDuchenne Muscular Dystrophy

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

22 November 2026FDA action datederamiocelPDUFA extended to 22 November 2026 for deramiocel
US, FDA · Capricor Therapeutics · Source ↗

Recent

22 August 2026FDA action datederamiocelPDUFA target action date set for deramiocel BLA
US, FDA · Source ↗
10 March 2026Filing acceptedderamiocelFDA lifts CRL and resumes review of deramiocel BLA
US, FDA · Capricor Therapeutics · Source ↗
3 December 2025Topline resultderamiocelHOPE-3 Phase 3 meets primary endpoint
Capricor Therapeutics · Source ↗
31 August 2025FDA action datederamiocelPDUFA target date set for deramiocel
US, FDA · Source ↗
11 July 2025Complete response letterderamiocelFDA issues a complete response letter for the deramiocel BLA
US, FDA · Capricor Therapeutics · Source ↗
4 March 2025Priority reviewderamiocelFDA grants Priority Review to deramiocel BLA
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$30M$45M+ $153M short-term inv.$43M-$36M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$29M$21M+ $217M short-term inv.$41M-$31M operating cash flowreport ↗
2026-Q1—$27M$105M+ $173M short-term inv.$34M-$29M operating cash flowreport ↗
2025-Q3—$20M$20M+ $79M short-term inv.$25M-$20M operating cash flowreport ↗
2025-Q2—$22M$23M+ $100M short-term inv.$26M-$20M operating cash flowreport ↗
2025-Q1—$19M$29M+ $116M short-term inv.$24M-$6.4M operating cash flowreport ↗
2024-Q3$2.3M$12M$68M+ $17M short-term inv.$13M-$12M operating cash flowreport ↗
2024-Q2$4.0M$13M$11M+ $19M short-term inv.$11M-$12M operating cash flowreport ↗
2024-Q1$4.9M$11M$6.2M+ $34M short-term inv.$9.8M-$1.3M operating cash flowreport ↗
2023-Q3$6.2M$10M$9.0M+ $20M short-term inv.$6.4M-$8.8M operating cash flowreport ↗
2023-Q2$3.9M$8.8M$9.8M+ $28M short-term inv.$7.4M-$9.4M operating cash flowreport ↗
2023-Q1$3.0M$7.7M$11M+ $35M short-term inv.$7.8M$4.2M operating cash flowreport ↗
2022-Q3$1.6M$5.5M$8.4M+ $38M short-term inv.$6.4M-$5.7M operating cash flowreport ↗
2022-Q2—$5.0M$16M+ $35M short-term inv.$7.1M-$6.5M operating cash flowreport ↗
2022-Q1—$5.1M$58M$7.8M$24M operating cash flowreport ↗
2021-Q3—$2.5M$41M$3.9M-$3.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$84M$288M+ $30M short-term inv.$26M-$70M operating cash flowreport ↗

Capricor reported full-year 2025 revenue of $0M, down 100.0% YoY from $22.27M, with R&D spend of $84.45M, up 69.0% YoY. Cash, cash equivalents and marketable securities totaled approximately $318.1M as of December 31, 2025, and the company reported a net loss of $105.04M for the year.

The company’s BLA for deramiocel in Duchenne muscular dystrophy remains under FDA review with a PDUFA target action date of August 22, 2026, supported by the HOPE-3 Phase 3 trial that met its primary and key secondary cardiac endpoints. Late-breaking HOPE-3 data presented at MDA 2026 showed additional cardiac and functional benefits, its San Diego GMP facility is operational for potential commercial launch, and the StealthX exosome-based vaccine Phase 1 trial is ongoing with final results expected in the second quarter of 2026. Capricor also completed an uplisting to the Nasdaq Global Select Market and expects its cash balance to support operations through 2027.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$22M$50M$11M+ $140M short-term inv.$10M-$40M operating cash flowreport ↗
2023-FY$25M$36M$15M+ $25M short-term inv.$5.6M-$26M operating cash flowreport ↗
2022-FY$2.5M$22M$9.6M+ $32M short-term inv.$7.3M$4.9M operating cash flowreport ↗
2021-FY$0.2M$14M$35M+ $0 short-term inv.$5.0M-$17M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 13 sales ($8.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-25Bergmann Anthony · CHIEF FINANCIAL OFFICEROption exercise24,100$3.18$77KForm 4
2026-06-25Krasney Karen · EVP, GENERAL COUNSELOption exercise24,100$3.18$77KForm 4
2026-06-25Bergmann Anthony · CHIEF FINANCIAL OFFICEROpen-market sale24,100$30.38$732KForm 4
2026-06-25Krasney Karen · EVP, GENERAL COUNSELOpen-market sale24,100$30.38$732KForm 4
2026-06-25Bergmann Anthony · CHIEF FINANCIAL OFFICEROption exercise (derivative)24,100——Form 4
2026-06-25Krasney Karen · EVP, GENERAL COUNSELOption exercise (derivative)24,100——Form 4
2026-06-24Bergmann Anthony · CHIEF FINANCIAL OFFICEROption exercise400$3.18$1KForm 4
2026-06-24Krasney Karen · EVP, GENERAL COUNSELOption exercise400$3.18$1KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 177 reporting institutions held 33.9M shares ($1.0B, 58.2% of shares outstanding).

#InstitutionSharesValue
1SUVRETTA CAPITAL MANAGEMENT, LLC3,818,600$116.1M
2BlackRock, Inc.3,421,815$104.0M
3TANG CAPITAL MANAGEMENT LLC3,399,900$103.4M
4STATE STREET CORP2,181,901$66.3M
5VANGUARD CAPITAL MANAGEMENT LLC2,027,732$61.6M
6RA CAPITAL MANAGEMENT, L.P.1,507,844$45.8M
7GEODE CAPITAL MANAGEMENT, LLC1,118,326$34.0M
8GOLDMAN SACHS GROUP INC911,976$27.7M
9Jones Hill Capital LP909,207$27.6M
10Point72 Asset Management, L.P.821,179$25.0M
11FMR LLC772,649$23.5M
12Boxer Capital Management, LLC590,000$17.9M
13JANE STREET GROUP, LLC566,081$17.2M
14J. Goldman & Co LP541,522$16.5M
15CITADEL ADVISORS LLC539,232$16.4M